Concepedia

Y. Loria-Kanza

YL

Statistics

Publications

4

Citations

203

H-Index

4

Active since

1995

Affiliations

Hôpital Saint-Louis(Current)

Novartis (France)

Y. Loria-Kanza is an author at Hôpital Saint-Louis specializing in pharmacotherapy, clinical pharmacology, and pharmacology.

Publications per year

1995–2007

4

Publications

4

Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease who Failed to Benefit from Treatment with Donepezil

Sophie Auriacombe, J.-J. Péré, Y. Loria-Kanza et al. · Current Medical Research and Opinion · 2002 · 116 citations

, , +17

Is Navoban® (tropisetron) as effective as Zofran® (ondansetron) in cisplatin-induced emesis?

Michel Marty, J.P. Kleisbauer, P. Fournel et al. · Anti-Cancer Drugs · 1995 · 40 citations

, , +17

Short‐duration topical treatment of tinea pedis using terbinafine emulsion gel: Results of a dose‐ranging clinical trial

Ian James, Y. Loria-Kanza, Thomas C. Jones · Journal of Dermatological Treatment · 2007 · 26 citations

, , +15

Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group.

Michel Marty, Kleisbauer Jp, P. Fournel et al. · PubMed · 1995 · 21 citations

, , +17

1–4 of 4